CN104003991A - Balasubramide, derivative of balasubramide, synthesis method and application - Google Patents

Balasubramide, derivative of balasubramide, synthesis method and application Download PDF

Info

Publication number
CN104003991A
CN104003991A CN201410260588.4A CN201410260588A CN104003991A CN 104003991 A CN104003991 A CN 104003991A CN 201410260588 A CN201410260588 A CN 201410260588A CN 104003991 A CN104003991 A CN 104003991A
Authority
CN
China
Prior art keywords
derivative
balasubramide
formula
application
nmr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201410260588.4A
Other languages
Chinese (zh)
Other versions
CN104003991B (en
Inventor
林汉森
庞涛
李建组
张陆勇
徐渊
宣宜宁
定力
李骏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangdong Pharmaceutical University
Original Assignee
Guangdong Pharmaceutical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangdong Pharmaceutical University filed Critical Guangdong Pharmaceutical University
Priority to CN201510756523.3A priority Critical patent/CN105343061B/en
Priority to CN201410260588.4A priority patent/CN104003991B/en
Publication of CN104003991A publication Critical patent/CN104003991A/en
Application granted granted Critical
Publication of CN104003991B publication Critical patent/CN104003991B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention discloses balasubramide, a derivative of the balasubramide, a synthesis method and the application. The structural formulas of the balasubramide and the derivative of the balasubramide are shown in the formula (I), the balasubramide and the derivative of the balasubramide have the superior nerve cell inflammation resistance activity and are free of cytotoxicity. Meanwhile, a scientific and reasonable synthesis route is designed, simplicity and high efficiency are achieved, the total yield of (+)-balasubramide is more than 45%, and the ee value is more than 97%.

Description

Balasubramide and derivative thereof and synthetic method and application
Technical field
The present invention relates to chemosynthesis and medical technical field, more specifically, relate to Balasubramide and
Derivative and synthetic method and application.
Background technology
1996, the chloroform extract of the Rutaceae clausena plant Cortex Clausenae Excavatae in Hofer Deng Cong Sri Lanka tropical rain forest [Clausena indica (Datz) .Oliv.] leaf was isolated biology precursor (+)-prebalamide of a kind of octatomic ring lactan composition (+)-balasubramide and (+)-balasubramide.
Rutaceae clausena plant is mainly distributed in south, the southeast in Asia, and minority is distributed in SOUTHERN CHINA and Australia.Interior nearly 30 kinds of world wide, has nearly 10 kinds within the border in China, is distributed in the middle and lower reach of Yangtze River and southern each province.The most plants of this genus is medicinal plant in China from ancient times, is used for the treatment of the diseases such as sense, malaria, stomachache and gastritis.Due to the importance of eight membered lactams structures and potential biological value, balasubramide and derivative thereof have important researching value, but have no at present the technology report of more heterogeneous pass chirality (+)-balasubramide and analogue thereof.
Yet the existing method of plant separation and Extraction of utilizing can obtain (+)-balasubramide, due to low separation efficiency and productive rate, is to be nowhere near for the research of its biologic activity aspect.Therefore, exploring a kind of (+)-balasubramide and analogue thereof that obtains chirality compared with the complete synthesis method of high separating efficiency and productive rate, is the key of its using value of research and development.
Complex construction and a plurality of chiral carbon atom due to eight membered lactams rings, up to now, rare pertinent literature report balasubramide's is synthetic, existing document relates to the synthetic report of balasubramide, disclosed synthetic method or reaction scheme are long, and productive rate is very low, or synthetic raw material preparation process is loaded down with trivial details, reaction conditions is special, has limited synthetic the production and promotion applied research of reality of balasubramide.Have no the synthetic of balasubramide related derivatives and utilisation technology report.
Summary of the invention
The technical problem to be solved in the present invention is the deficiency that overcomes existing Balasubramide derivative, and the Balasubramide derivative that a class is new is provided.
Another technical problem that the present invention will solve is to provide the application of described Balasubramide derivative.
Another technical problem that the present invention will solve is to provide that a kind of step is simple, raw material is easy to get, productive rate is higher
Preparation method, based on described preparation method, can obtain Balasubramide of the present invention and derivative thereof.
The also technical problem that the present invention will solve is to provide and adopts Balasubramide that described preparation method prepares and the application of derivative thereof.
Object of the present invention is achieved by the following technical programs:
The derivative of Balasubramide is provided, and its structural formula is as shown in formula I:
（Ⅰ），
Wherein, R 1for H or-CH 3; R is Ph, 3-F-C 6h 4, 4-F-C 6h 4, 3-Cl-C 6h 4, 4-Cl-C 6h 4, 3-Br-C 6h 4, 4-Br-C 6h 4, 4-NO 2-C 6h 4or 3-CF 3-C 6h 4.
The application of the derivative of described Balasubramide aspect the preparation treatment cerebral protection medicine relevant to neurocyte provides described Balasubramide derivative in the application of preparing aspect anti-neuritis disease drug simultaneously.
R in structure shown in preferred formula I 1for H and R are 4-F-C 6h 4time compound in the application aspect the preparation treatment cerebral protection medicine relevant to neurocyte, and in the application of preparing aspect anti-neuritis disease drug.
The preparation method who the invention provides a kind of Balasubramide and derivative thereof, comprises the following steps:
S1. one kettle way catalysis trans-Cinnamylaldehyde and derivative epoxidation thereof, obtain α, beta epoxide carboxylicesters;
S2. by S1 gained α, beta epoxide carboxylicesters and tryptamines and analogue effect thereof, obtain prebalamide and derivative thereof;
S3. with Yb (CF 3sO 3) 3for catalyzer, make the prebalamide or derivatives thereof cyclization respectively of S2 gained, synthetic (+)-balasubramide and derivative thereof.
Wherein, described in S1, one kettle way catalysis trans-Cinnamylaldehyde and derivative epoxidation thereof comprise the following steps:
S11. under condition of ice bath, with 40% (V/V) H 2o 2the aqueous solution is oxygenant, uses the S-diphenylprolinol triethyl silicon a series of trans-Cinnamylaldehyde of ether catalysis and derivative epoxidation thereof;
S12. at ambient temperature, S11 gained reaction solution dilutes with methyl alcohol, adds NBS(N-bromosuccinimide, N-bromosuccinimide) and sodium carbonate, synthetic α, beta epoxide carboxylicesters.
The invention provides based on the synthetic Balasubramide of described preparation method and derivative thereof.Structural formula is as shown in formula I:
（Ⅰ），
Wherein, R 1for H or-CH 3; R is Ph, 3-F-C 6h 4, 4-F-C 6h 4, 3-Cl-C 6h 4, 4-Cl-C 6h 4, 3-Br-C 6h 4, 4-Br-C 6h 4, 4-NO 2-C 6h 4or 3-CF 3-C 6h 4.
The present invention provides the application aspect the preparation treatment cerebral protection medicine relevant to neurocyte of the Balasubramide for preparing based on described preparation method and derivative thereof simultaneously, provides described Balasubramide derivative in the application of preparing aspect anti-neuritis disease drug simultaneously.
Beneficial effect of the present invention:
The invention provides a class high antimer selectivity Balasubramide derivative, filled up and had the blank or not enough of optical activity eight membered lactams structural compounds, for the research of relevant chirality (+)-balasubramide and analogue thereof, applied strong technical foundation is provided.
The invention provides synthetic line and synthetic method that described Balasubramide and derivative thereof are new, designed the asymmetric synthesis route of one (+)-balasubramide, successfully synthesize Balasubramide and derivative thereof.First the present invention has designed scientific and reasonable synthetic line, optimized key intermediate α, the synthetic processing condition of beta epoxide carboxylicesters, adopt the one kettle way of optimizing to synthesize a series of α, beta epoxide carboxylicesters, has obtained the highest 80% productive rate and 97% ee value.Result shows, the one kettle way of optimization provided by the present invention is prepared asymmetric Epoxidation and the oxidative esterification of alpha, beta-unsaturated esters, is synthetic α, the simple method efficiently of beta epoxide carboxylicesters.Further, based on the present invention optimize high ee value that one kettle way catalysis trans-Cinnamylaldehyde and derivative epoxidation thereof obtain α, beta epoxide carboxylicesters, by itself and tryptamines and analogue effect thereof, has obtained prebalamide and derivative thereof, then with Yb (CF 3sO 3) 3for catalyzer, make prebalamide cyclization, synthesized natural product (+)-balasubramide and derivative thereof.By optimizing reaction conditions, the present invention has obtained higher yield and enantioselectivity.Wherein, the total recovery of (+)-balasubramide is more than 45%, and ee value is more than 97%.
The invention provides the new application of described Balasubramide derivative, Balasubramide derivative all has the inflammatory reaction effect that suppresses significantly microglia generation, and meanwhile, cytotoxicity experiment shows that these compounds do not have cytotoxicity.
Accompanying drawing explanation
The cerebral protection experimental result of the nerve injury that Fig. 1 the compounds of this invention causes the cultured rat cerebellar granule neurone nutritive deficiency of former culture.
The cerebral protection of tested group of compound of Fig. 2 to the PC12 neural cell injury of hydrogen peroxide-induced.
The provide protection of tested group of compound of Fig. 3 in the primary cultured rat cerebellar granule neural cell injury of Pidolidone induction.
The restraining effect that Fig. 4 test-compound discharges inflammatory factor TNFalpha in lipopolysaccharide-induced BV-2 microglia.
The cytotoxic effect of Fig. 5 test-compound to BV-2 microglia.
Embodiment
Below in conjunction with the drawings and specific embodiments, further illustrate the present invention.Unless stated otherwise, the reagent that the present invention adopts and and equipment be conventional reagent and the equipment using in this area.
embodiment 1the synthetic method condition research experiment of Balasubramide derivative
One, optical activity alpha, beta epoxide carboxylicesters synthetic
The method of reference literature report, we are by optimizing reaction conditions, with 40% H 2o 2the aqueous solution is oxygenant, use homemade chiral imines class catalyst S-diphenylprolinol triethyl silicon a series of trans-Cinnamylaldehyde of ether catalysis and derivative epoxidation thereof, after room temperature reaction 4 h, with methyl alcohol dilution, then add NBS and sodium carbonate oxidative esterification, room temperature 3 h, obtained (2S, 3R)-α, beta epoxide carboxylicesters, the latter has good productive rate and outstanding ee value.By the specific rotation data of contrast document, the absolute configuration of final product is defined as 2S, 3R.The results are shown in Table shown in 1.
Reaction scheme is:
Table 1
Two, by α, the synthetic prebalamide of beta epoxide carboxylicesters and derivative thereof
1. the impact of reaction conditions on compound 2 productive rates
The present invention be take methyl alcohol as solvent, at ambient temperature, beta-phenyl glycidic acid methyl esters and the condensation of tryptamines generation ester amine, reaction 3 h, have obtained product 2h.But, productive rate 55%.Further research is found under cold condition, adds the alkali of catalytic amount can significantly improve the yield of reaction.Investigated and reacted the impact of various additives on reaction, result is as shown in table 3.
Reaction scheme is as follows:
Table 2
Research finds that the power of additive alkalescence has significant impact to reaction result.Add NaHCO 3, K 2cO 3and Na 2cO 3very micro-on the impact of reaction yield, and add catalytic amount t-BuOK and NaOCH 3during in highly basic, the productive rate of reaction has significantly improved.Wherein, when take t-BuOK during as additive, obtained 81% productive rate.Therefore, the present invention select t-BuOK be reaction condensing agent.
Three, target product is synthetic
The present invention be take acetonitrile as solvent, trifluoromethanesulfonic acid ytterbium (Yb (CF 3sO 3) 3) be catalyzer, by prebalamide and derivative thereof, synthesized (+)-balasubramide and derivative thereof.In addition, the present invention has investigated the impact of differential responses condition on ring-closure reaction.
1., on epoxy reactive impact, experimental result is as shown in table 3 for Lewis acid (lewis acid):
Reaction scheme is given an example:
Table 3
As can be seen from Table 3, select different Lewis acids, the productive rate of ring-closure reaction produces significantly difference.Add active strong Lewis acid, as AlCl 3, FeCl 3, CuCl, there is no the generation of target product.Add active weak Lewis acid LaCl 3time, the generation of target product detected, but productive rate is only 33%.When adding Yb (CF 3sO 3) 3, during the Lewis acids such as p-TSA, cyclisation product reaction obtain medium productive rate and outstanding corresponding selection.Wherein add Yb (CF 3sO 3) 3obtained best result, productive rate be 73% and ee value be 97%.
2. reaction solvent is on epoxy reactive impact
At definite Yb (CF 3sO 3) 3after cyclization catalyst, the present invention has investigated the impact of reaction solvent on reaction, and result is as shown in table 5.
Reaction scheme is as follows:
Table 4
Project Solvent Yield (%) Ee(%)
1 CHCl 3 67 97
2 THF 75 97
3 CH 3CN 73 97
4 DMF 72 97
5 DMSO 70 97
As can be seen from Table 4, ring-closure reaction can carry out smoothly in most of solvent, and the not impact of solvent on the ee value of product.Compare non-polar solvent as CHCl 3solvent, reaction obtains better productive rate in polar solvent.Wherein, take THF as solvent, reaction has the highest productive rate, has reached 75%.Synthesis condition for other derivatives is studied with above-mentioned experimental result.
embodiment 2
The whole synthetic route of optical activity (+)-balasubramide derivative is as follows:
Obtain (+)-balasubramide derivative 3a～3j, the R in structural formula is respectively shown in table 5:
Table 5
Sequence number Structure
3a R=3-F-C 6H 4 , R 1＝H
3b R=4-F-C 6H 4 , R 1＝H
3c R=3-CF 3-C 6H 4 , R 1＝H
3d R=3-Br-C 6H 4 , R 1＝H
3e R=4-Cl-C 6H 4 , R 1＝H
3f R=4-Br-C 6H 4 , R 1＝H
3g R=3-Cl-C 6H 4 , R 1＝H
3h R=Ph , R 1＝H
3i R=4-NO 2-C 6H 4 , R 1＝H
3j R=Ph, R 1＝Me
The structure of (+)-balasubramide derivative 3a～3j is as follows:
3a 3b 3c 3d
3e 3f 3g 3h
3i 3j
Each step compound experiment:
1. compound 1a-1j's is synthetic
1
Trans-Cinnamylaldehyde and derivative 3.9 g thereof are dissolved in to 30 ml methylene dichloride, then add catalyzer 1.1g ~ 1.3 g and aqueous hydrogen peroxide solution 3.5 ~ 4.3 ml, room temperature reaction 2 h, add 30 ml methyl alcohol dilutions, then add successively Na 2cO 33.8 ~ 4.5 g and N-bromo-succinimide 6.4 ~ 7.3 g, continue reaction 3 h, after reaction finishes, filters, and filtrate decompression is steamed and desolventized, residue purification by silica gel column chromatography.
, weak yellow liquid shape, 65% yield, [α] d 20=+166.2 (0.5, CHCl 3); 1h NMR (500 MHz, CDCl 3) δ 7.34 (td, j=8.0,5.7 Hz, 1H), 7.10 (d, j=7.7 Hz, 1H), 7.04 (td, j=8.4,2.6 Hz, 1H), 7.01-6.95 (m, 1H), 4.10 (t, j=3.3 Hz, 1H), 3.83 (s, 3H), 3.48 (d, j=1.7 Hz, 1H); IR (KBr) v/cm -1: 1752,1634,1442,1292,1233,1210,777,686.
1b, weak yellow liquid shape, 63% yield, [α] d 20=+132.2 (0.5, CHCl 3); 1h NMR (400 MHz, CDCl 3) δ 7.22 – 7.16 (m, 2H), 7.02 – 6.95 (m, 2H), 4.02 (t, j=3.7 Hz, 1H), 3.76 (d, j=5.6 Hz, 3H), 3.42 (dd, j=7.8,2.2 Hz, 1H); IR (KBr) v/cm -1: 1749,1637,1442,1290,1243,1214,775,686.
, colorless oil 75% yield, [α] d 20=+128.3 (0.5, CHCl 3); 1h NMR (500 MHz, CDCl 3) δ 7.63 (t, j=7.1 Hz, 1H), 7.56 (s, 1H), 7.54 – 7.47 (m, 2H), 4.17 (d, j=1.6 Hz, 1H), 3.85 (s, 3H), 3.51 (d, j=1.7 Hz, 1H); IR (KBr) v/cm -1: 1755,1636,1405,1328,1125,700,662.
1d, white solid, 71% yield, 55～57 ° of C of m.p., [α] d 20=+135.2 (0.5, CHCl 3); 1h NMR (500 MHz, CDCl 3) δ 7.51 – 7.45 (m, 1H), 7.43 (s, 1H), 7.23 (ddd, j=5.3,3.9,1.5 Hz, 2H), 4.07 (d, j=1.7 Hz, 1H), 3.83 (s, 3H), 3.48 (d, j=1.6 Hz, 1H). IR (KBr) v/cm -1: 1758,1450,1341,1208,991,880,784,746,685.
1e, white solid, 88% yield, 49～52 ° of C of m.p., [α] d 20=+147.7 (0.5, CHCl 3), [lit [60]: [α] d 20=+145.7 (0.5, CHCl 3)]; 1h NMR (500 MHz, CDCl 3) δ 7.31 (dd, j=6.5,4.5 Hz, 2H), 7.27 (t, j=3.7 Hz, 1H), 7.19 (dt, j=7.0,1.6 Hz, 1H), 4.08 (d, j=1.6 Hz, 1H), 3.83 (s, 3H), 3.48 (d, j=1.7 Hz, 1H); IR (KBr) v/cm -1: 1747,1638,1436,1401,1209,784,686.
1f, white solid, 63% yield, 73～74 ° of C of m.p., [α] d 20=+129.6 (0.5, CHCl 3), [lit [60]: m.p. 69-70 ° C, [α] d 20=+127.6 (0.5, CHCl 3)]; 1h NMR (500 MHz, CDCl 3) δ 7.52 – 7.50 (m, 1H), 7.50 – 7.48 (m, 1H), 7.19 – 7.17 (m, 1H), 7.17 – 7.15 (m, 1H), 4.07 (d, j=1.6 Hz, 1H), 3.83 (s, 3H), 3.47 (d, j=1.7 Hz, 1H); IR (KBr) v/cm -1: 1751,1493,1425,1339,1211,1091,835,793.
1g, white solid, 88% yield, 58～59 ° of C of m.p., [α] d 20=+155.1 (0.5, CHCl 3), [lit [60]: [α] d 20=+150.6 (0.5, CHCl 3)]; 1h NMR (500 MHz, CDCl 3) δ 7.36 – 7.33 (m, 1H), 7.33 – 7.31 (m, 1H), 7.24 – 7.22 (m, 1H), 7.22 – 7.20 (m, 1H), 4.08 (d, j=1.6 Hz, 1H), 3.82 (s, 3H), 3.47 (d, j=1.7 Hz, 1H); IR (KBr) v/cm -1: 2955,1752,1496,1445,1290,1211,1091,835,739.
, weak yellow liquid shape, 78% yield, [α] d 20=+156.3 (0.5, CHCl 3), [lit [60]: [α] d 20=+157.1 (0.5, CHCl 3)]; 1h NMR (500 MHz, CDCl 3) δ 7.40 – 7.34 (m, 3H), 7.32 – 7.28 (m, 2H), 4.11 (t, j=2.7 Hz, 1H), 3.83 (s, 3H), 3.53 (d, j=1.8 Hz, 1H); IR (KBr) v/cm -1: 2955,1750,1634,1440,1413,1201,760,696.
1i, weak yellow liquid shape, 88% yield, 137～138 ° of C of m.p., [α] d 20=+150.1 (0.5, CHCl 3), [lit [60]: m.p. 137-139, [α] d 20=+151.6 (0.5, CHCl 3)]; 1h NMR (500 MHz, CDCl 3) δ 8.25 (s, 1H), 8.23 (s, 1H), 7.49 (s, 1H), 7.47 (s, 1H), 4.22 (d, j=1.5 Hz, 1H), 3.85 (s, 3H), 3.50 (d, j=1.6 Hz, 1H); IR (KBr) v/cm -1: 1750,1606,1518,1349,1216,863,735,690.
2. compound 2a-2j's is synthetic
1 2
(R wherein 1=H tryptamines, R 1=Me methyltryptamine)
Tryptamines or N-mehtyltryptamine 1.0g are dissolved in 30 ml methyl alcohol, ice bath is cooled to 5 ℃, then drips potassium tert.-butoxide 112 mg methanol solution 10 ml, adds 1a ~ 1j 1.6 ~ 2.3 g after dropwising, maintain this thermotonus 3 h, after finishing, reaction removes solvent under reduced pressure, 50 ml dichloromethane solvents for residue, distilled water wash for organic phase (10ml * 3), anhydrous sodium sulfate drying, remove solvent under reduced pressure, residue column chromatography purification, obtains.
, white solid, 81% yield, 138～140 ° of C of m.p., [α] d 20=+45.1 (0.5, CHCl 3); 1h NMR (500 MHz, CDCl 3) δ 8.18 (s, 1H), 7.62 (d, j=7.9 Hz, 1H), 7.45 – 7.37 (m, 1H), 7.30 (td, j=8.0,5.7 Hz, 1H), 7.24 (t, j=7.5 Hz, 1H), 7.16 (dd, j=7.8,7.1 Hz, 1H), 7.06 (d, j=2.0 Hz, 1H), 7.05 – 6.97 (m, 2H), 6.91 – 6.85 (m, 1H), 6.29 (s, 1H), 3.72 – 3.59 (m, 3H), 3.43 (d, j=1.8 Hz, 1H), 3.11 – 2.95 (m, 2H); IR (KBr) v/cm -1: 3313,1638,1557,1458,1248,743,610.
2b, white solid, 80% yield, 119～121 ° of C of m.p., [α] d 20=+47.3 (0.5, CHCl 3); 1h NMR (400 MHz, DMSO) δ 10.82 (s, 1H), 8.26 (t, j=5.6 Hz, 1H), 7.55 (d, j=7.8 Hz, 1H), 7.44 – 7.29 (m, 3H), 7.21 (dd, j=18.5,9.8 Hz, 3H), 7.07 (t, j=7.5 Hz, 1H), 6.98 (t, j=7.4 Hz, 1H), 4.02 (s, 1H), 3.58 (d, j=1.5 Hz, 1H), 3.47 – 3.35 (m, 2H), 2.88 (t, j=7.3 Hz, 2H); IR (KBr) v/cm -1: 3448,1639,1556,1514,1228,839,743,615.
2c, white solid, 89% yield, 127～130 ° of C of m.p., [α] d 20=+36.2 (0.5, CHCl 3); 1h NMR (500 MHz, CDCl 3) δ 8.12 (s, 1H), 7.63 (d, j=7.9 Hz, 1H), 7.59 (d, j=7.6 Hz, 1H), 7.47 (t, j=7.8 Hz, 1H), 7.45 – 7.39 (m, 2H), 7.37 (d, j=7.7 Hz, 1H), 7.24 (d, j=7.3 Hz, 1H), 7.17 (t, j=7.4 Hz, 1H), 7.08 (d, j=2.2 Hz, 1H), 6.28 (s, 1H), 3.74 – 3.59 (m, 3H), 3.45 (d, j=1.9 Hz, 1H), 3.13-2.96 (m, 2H); IR (KBr) v/cm -1: 3414,1638,1558,1322,1140,746,611.
2d, white solid, 83% yield, 168～172 ° of C of m.p., [α] d 20=+55.8 (0.5, CHCl 3); 1h NMR (500 MHz, CDCl 3) δ 8.14 (s, 1H), 7.62 (d, j=7.9 Hz, 1H), 7.46 (d, j=8.0 Hz, 1H), 7.40 (d, j=8.1 Hz, 1H), 7.32 (d, j=1.6 Hz, 1H), 7.26-7.10 (m, 4H), 7.07 (d, j=2.0 Hz, 1H), 6.27 (s, 1H), 3.65 (tq, j=13.4,6.7 Hz, 2H), 3.59 (t, j=3.0 Hz, 1H), 3.42 (d, j=1.9 Hz, 1H), 3.11 – 2.95 (m, 2H); IR (KBr) v/cm -1: 3313,1638,1556,1432,1248,744,617.
2e, white solid, 81% yield, 160～163 ° of C of m.p., [α] d 20=+40.1 (0.5, CHCl 3); 1h NMR (400 MHz, DMSO) δ 10.82 (s, 1H), 8.28 (t, j=5.7 Hz, 1H), 7.55 (d, j=7.8 Hz, 1H), 7.45 (d, j=8.5 Hz, 2H), 7.43 – 7.32 (m, 3H), 7.17 (d, j=2.1 Hz, 1H), 7.08 (dd, j=11.0,4.0 Hz, 1H), 6.99 (dd, j=11.0,3.8 Hz, 1H), 4.03 (d, j=1.7 Hz, 1H), 3.57 (d, j=1.9 Hz, 1H), 3.41 (dd, j=13.4,7.2 Hz, 2H), 2.88 (t, j=7.4 Hz, 2H); IR (KBr) v/cm -1: 3313,1639,1551,1431,1092,1012,742,614.
2f, white solid, 89% yield, 177～179 ° of C of m.p., [α] d 20=+55.3 (0.5, CHCl 3); 1h NMR (400 MHz, DMSO) δ 10.82 (s, 1H), 8.28 (t, j=5.6 Hz, 1H), 7.57 (dd, j=13.6,8.1 Hz, 3H), 7.32 (dd, j=18.6,8.2 Hz, 3H), 7.17 (d, j=1.7 Hz, 1H), 7.07 (t, j=7.4 Hz, 1H), 6.98 (t, j=7.4 Hz, 1H), 4.02 (d, j=1.4 Hz, 1H), 3.56 (d, j=1.7 Hz, 1H), 3.41 (dd, j=13.4,7.0 Hz, 2H), 2.87 (t, j=7.3 Hz, 2H); IR (KBr) v/cm -1: 3313,1638,1551,1458,1431,1092,742,614.
, white solid, 88% yield, 159～153 ° of C of m.p., [α] d 20=+34.1 (0.5, CHCl 3); 1h NMR (500 MHz, CDCl 3) δ 8.17 (s, 1H), 7.62 (d, j=7.9 Hz, 1H), 7.40 (d, j=8.1 Hz, 1H), 7.33-7.29 (m, 1H), 7.27 (d, j=7.6 Hz, 1H), 7.24 (t, j=6.6 Hz, 1H), 7.16 (q, j=6.7 Hz, 2H), 7.10 – 7.04 (m, 2H), 6.28 (s, 1H), 3.70 – 3.61 (m, 2H), 3.60 (d, j=1.9 Hz, 1H), 3.43 (d, j=1.9 Hz, 1H), 3.11 – 2.95 (m, 2H); IR (KBr) v/cm -1: 3313,1638,1556,1458,1430,744,617.
2h, white solid, 88% yield, 131～133 ° of C of m.p., [α] d 20=+33.1 (0.5, CHCl 3), [lit [1]: m.p. 125-127, [α] d=+30 (0.5, CHCl 3)]; 1h NMR (500 MHz, CDCl 3) δ 8.11 (s, 1H), 7.63 (d, j=7.9 Hz, 1H), 7.40 (d, j=8.1 Hz, 1H), 7.37 – 7.30 (m, 3H), 7.23 (dd, j=11.2,4.0 Hz, 1H), 7.20 (dd, j=6.5,3.1 Hz, 2H), 7.16 (t, j=7.4 Hz, 1H), 7.08 (d, j=2.2 Hz, 1H), 6.31 (s, 1H), 3.66 (dt, j=13.0,4.2 Hz, 3H), 3.49 (d, j=2.0 Hz, 1H), 3.10 – 2.96 (m, 2H); IR (KBr) v/cm -1: 3310,1638,1556,1458,1432,743,616.
2i, white solid, 69% yield.m.p. 167～169 °C, [α] D 20 = +73.2 (0.5, CHCl 3); 1H NMR (500 MHz, CDCl 3) δ 8.23 – 8.21 (m, 1H), 8.21 – 8.19 (m, 1H), 8.11 (s, 1H), 7.63 (d, J = 7.9 Hz, 1H), 7.41 (d, J = 8.1 Hz, 1H), 7.38 – 7.32 (m, 2H), 7.24 (dd, J = 8.1, 1.1 Hz, 1H), 7.20 – 7.14 (m, 1H), 7.09 (d, J = 2.3 Hz, 1H), 6.26 (s, 1H), 3.76 – 3.59 (m, 3H), 3.44 (d, J = 1.9 Hz, 1H), 3.14 – 2.95 (m, 2H)。IR (KBr) v/cm -1: 3310, 1639, 1522, 1348, 748, 612。
, white solid, 80% yield, 135～137 ° of C of m.p., [α] d 20=+35.1 (0.5, CHCl 3), 1h NMR (500 MHz, CDCl 3) δ 8.11 (s, 1H), 7.63 (d, j=7.9 Hz, 1H), 7.40 (d, j=8.1 Hz, 1H), 7.37 – 7.30 (m, 3H), 7.23 (dd, j=11.2,4.0 Hz, 1H), 7.20 (dd, j=6.5,3.1 Hz, 2H), 7.16 (t, j=7.4 Hz, 1H), 7.08 (d, j=2.2 Hz, 1H), 3.66 (dt, j=13.0,4.2 Hz, 3H), 3.49 (d, j=2.0 Hz, 1H), 3.10 – 2.96 (m, 2H), 2.90 (s, 3H); IR (KBr) v/cm -1: 3315,1630,1550,1458,1432,743,616.
3. compound 3a-3j's is synthetic
2a～2j 670 ~ 744 mg are dissolved in the THF that 30 ml are dry, then add trifluoromethanesulfonic acid ytterbium 58 ~ 64 mg.Room temperature reaction spends the night, and after reaction finishes, removes solvent under reduced pressure, and residue adds 50 ml methylene dichloride to dissolve, and then uses saturated NaCl solution (10 ml * 3) washing, wash 1 time, anhydrous sodium sulfate drying, removes solvent under reduced pressure, obtain dope, crude product, through column chromatography purification, obtains.
3a, white solid, 76% yield, m.p. 114-116 ° C, [α] d 20=+33 (c=0.5, MeOH); 1h NMR (500 MHz, DMSO) δ 10.79 (s, 1H), 7.99 (t, j=5.8 Hz, 1H), 7.49 (d, j=7.8 Hz, 1H), 7.40 – 7.30 (m, 2H), 7.25 (dd, j=17.1,8.9 Hz, 2H), 7.05 (dd, j=14.2,6.5 Hz, 2H), 6.97 (t, j=7.4 Hz, 1H), 5.40 (d, j=4.6 Hz, 1H), 4.42 – 4.34 (m, 1H), 3.36 (s, 1H), 3.35 – 3.15 (m, 2H), 2.68 – 2.52 (m, 2H); 13c NMR (126 MHz, DMSO) δ 169.71,160.21,136.20,129.75,127.07,124.80; 122.44,120.93,118.21,115.63,115.45,115.16,115.00; 111.51,111.33,75.24,62.61,40.02,25.00; IR (KBr) v/cm -1: 3421,1637,1538,1488,1452,1275,1236,1114,789,696; HRMS (ES +) caculated for C 19h 17o 2n 2f [M+Na] +=347.1163, found=347.1167; Ee value is determined (4.6 mm * 25 cm, n-hexane/i-PrOH=90/10, λ=254nm, 0.8 ml/min), t by chiralcel AD-H post by chirality HPLC minor=31.5 min, t major=35.1 min, 97% ee.
3b,white solid, 70% yield, m.p. 88-91 ° C, [α] d 20=+45 (c=0.5, MeOH); 1h NMR (500 MHz, DMSO) δ 10.79 (s, 1H), 7.95 (t, j=5.9 Hz, 1H), 7.52 – 7.43 (m, 3H), 7.32 (d, j=8.1 Hz, 1H), 7.14 (t, j=8.9 Hz, 2H), 7.04 (dd, j=4.0,1.5 Hz, 1H), 6.97 (t, j=7.4 Hz, 1H), 5.39 (d, j=4.7 Hz, 1H), 4.36 (dd, j=6.4,5.0 Hz, 1H), 3.34 (s, 1H), 3.32 – 3.16 (m, 2H), 2.70 – 2.53 (m, 2H); 13c NMR (126 MHz, DMSO) δ 169.80,161.06,136.21,133.75,130.80; 127.07,122.47,120.93,118.21,114.72,114.54; 111.51,111.33,75.33,62.79,40.02,25.00; IR (KBr) v/cm -1: 3492,1634,1506,1116,1088,879,745,670; HRMS (ES +) caculated for C 19h 17o 2n 2f [M+Na] +=347.1151, found=347.1154; Ee value is determined (4.6 mm * 25 cm, n-hexane/i-PrOH=90/10, λ=254nm, 0.8 ml/min), t by chiralcel AD-H post by chirality HPLC minor=32.0 min, t major=37.3 min, >99% ee.
3c, white powder, 75% yield, m.p. 94-96 ° C, [α] d 20=+41 (c=0.5, MeOH); 1h NMR (500 MHz, DMSO) δ 10.78 (s, 1H), 7.99 (t, j=5.9 Hz, 1H), 7.72 (d, j=7.8 Hz, 1H), 7.68 (d, j=7.8 Hz, 1H), 7.56 (t, j=7.8 Hz, 1H), 7.47 (d, j=7.8 Hz, 1H), 7.32 (d, j=8.1 Hz, 1H), 7.08 – 7.03 (m, 1H), 7.01 (d, j=2.2 Hz, 1H), 6.98 – 6.94 (m, 1H), 5.54 (d, j=4.5 Hz, 1H), 4.42 (dd, j=6.4,4.6 Hz, 1H), 3.33 – 3.11 (m, 2H), 2.64 – 2.52 (m, 2H); 13c NMR (126 MHz, DMSO) δ 169.62,138.71,136.20; 132.89,128.99,127.05,125.17; 125.00,122.39,120.93,118.21; 118.18,111.47,111.41; 75.17,62.62,39.94; 39.85,39.01,24.97; IR (KBr) v/cm -1: 3436,1647,1342,1122,802,746,705; HRMS (ES +) caculated for C 20h 17o 2n 2f 3[M+Na] +=397.1190, found=397.1194; Ee value is determined (4.6 mm * 25 cm, n-hexane/i-PrOH=90/10, λ=254nm, 0.8 ml/min), t by chiralcel AD-H post by chirality HPLC minor=20.4 min, t major=21.4 min, 96% ee.
3d, white powder, 60% yield, m.p. 120-123 ° C, [α] d 20=-61 (c=0.5, MeOH); 1h NMR (500 MHz, DMSO) δ 10.84 (s, 1H), 8.31 (s, 1H), 7.55 (d, j=8.1 Hz, 3H), 7.35 (s, 3H), 7.07 (t, j=7.3 Hz, 1H), 6.98 (t, j=7.2 Hz, 1H), 4.03 (s, 1H), 3.60 (s, 1H), 3.41 (d, j=6.1 Hz, 2H), 2.87 (t, j=6.9 Hz, 2H); 13c NMR (126 MHz; DMSO) δ 166.10 (s); 138.78 (s), 136.23 (s), 131.50 (s); 130.73 (s); 128.72 (s), 127.24 (s), 125.13 (s); 122.76 (s); 121.87 (s), 120.93 (s), 118.25 (s); 111.53; 111.39,58.15 (s), 55.78 (s); 40.02 (s), 24.94 (s); IR (KBr) v/cm -1: 3399,1644,1537,1427,1342,1248,787,738,692; HRMS (ES +) caculated for C 19h 17o 2n 2br [M+Na] +=407.0352, found=407.0351; Ee value is determined (4.6 mm * 25 cm, n-hexane/i-PrOH=90/10, λ=254nm, 0.8 ml/min), t by chiralcel AD-H post by chirality HPLC minor=31.6 min, t major=35.7 min, 97% ee.
3e, white powder, 65% yield, m.p. 151-161 ° C, [α] d 20=+56 (c=0.5, MeOH); 1h NMR (400 MHz, DMSO) δ 10.78 (s, 1H), 7.94 (t, j=5.8 Hz, 1H), 7.50 (d, j=7.8 Hz, 1H), 7.40 (dd, j=22.4,8.6 Hz, 4H), 7.33 (d, j=8.1 Hz, 1H), 7.04 (s, 1H), 6.97 (t, j=7.4 Hz, 1H), 5.39 (d, j=4.7 Hz, 1H), 4.37 (dd, j=6.5,4.8 Hz, 1H), 3.32 – 3.19 (m, 2H), 2.72 – 2.52 (m, 2H); 13c NMR (101 MHz, DMSO) δ 169.68 (s), 136.39 (s), 136.18 (s), 132.80 (s), 130.49 (s), 127.77 (s), 127.05 (s), 122.42 (s), 120.89 (s), 118.17 (s), 111.39 (d j=19.2 Hz), 75.22 (s), 62.67 (s), 40.13 (s), 24.95 (s); IR (KBr) v/cm -1: 3366,2956,1638,1538,1491,1458,1413,1091,1036,922,814,744; Ee value is determined (4.6 mm * 25 cm, n-hexane/i-PrOH=90/10, λ=254nm, 0.8 ml/min), t by chiralcel AD-H post by chirality HPLC minor=31.9 min, t major=36.9 min, >99% ee.
3f, white powder, 66% yield, m.p. 147-150 ° C, [α] d 20=+58 (c=0.5, MeOH); 1h NMR (500 MHz, DMSO) δ 10.85 (s, 1H), 8.00 (s, 1H), 7.50 (t, j=9.2 Hz, 3H), 7.34 (dd, j=14.9,8.3 Hz, 3H), 7.05 (d, j=2.7 Hz, 1H), 6.97 (t, j=7.4 Hz, 1H), 5.37 (d, j=4.7 Hz, 1H), 4.36 (t, j=5.6 Hz, 1H), 3.33 – 3.17 (m, 2H), 2.69 – 2.54 (m, 2H); 13c NMR (126 MHz, DMSO) δ 172.45,136.88,136.20,130.85,130.75,127.06,122.47,121.45,120.90,118.20,111.48,111.35,75.17,62.73,39.51,24.99; IR (KBr) v/cm -1: 3408,1656,1640,1196,1122,804,744,667; HRMS (ES +) caculated for C 19h 17o 2n 2br [M+Na] +=407.3332, found=407.3338; Ee value is determined (4.6 mm * 25 cm, n-hexane/i-PrOH=90/10, λ=254nm, 0.8 ml/min), t by chiralcel AD-H post by chirality HPLC minor=34.9 min, t major=39.6 min, >99% ee.
3g, white solid, 62% yield, m.p. 178-181 ° C, [α] d 20=+120 (c=0.5, MeOH); 1h NMR (500 MHz, DMSO) δ 10.79 (s, 1H), 7.99 (t, j=5.8 Hz, 1H), 7.55 – 7.46 (m, 2H), 7.35 (m, 4H), 7.06 (d, j=7.8 Hz, 1H), 6.97 (t, j=7.4 Hz, 1H), 5.40 (d, j=4.6 Hz, 1H), 4.37 (dd, j=6.3,4.8 Hz, 1H), 3.33 – 3.13 (m, 2H), 2.69 – 2.52 (m, 2H); 13c NMR (126 MHz, DMSO) δ 169.66,139.74,136.20,132.42,129.70,128.52; 128.17,127.42,127.06,122.43,120.92,118.21; 111.50,111.33,75.19,62.60,39.51,25.03; IR (KBr) v/cm -1: 3425,1634,1536,1430,1114,747,706; HRMS (ES +) caculated for C 19h 17o 2n 2cl [M+Na] +=363.0862, found=363.0865; Ee value is determined (4.6 mm * 25 cm, n-hexane/i-PrOH=90/10, λ=254nm, 0.8 ml/min), t by chiralcel AD-H post by chirality HPLC minor=29.7 min, t major=34.0 min, 97% ee.
3h, white solid, 78% yield, 127～130 ° of C of m.p., [α] d 20=+30 (c=0.5, MeOH); 1h NMR (400 MHz, DMSO) δ 10.85 (s, 1H), 7.51 (d, j=7.7 Hz, 1H), 7.36 (d, j=7.5 Hz, 2H), 7.29 (t, j=7.5 Hz, 3H), 7.20 (t, j=7.2 Hz, 2H), 7.07 – 6.93 (m, 2H), 4.88 (d, j=9.9 Hz, 1H), 4.21 (d, j=9.9 Hz, 1H), 3.68 (s, 1H), 3.32 – 3.17 (m, 3H), 1.25 (s, 1H); 13c NMR (101 MHz, DMSO) δ 175.94,141.65,135.77,135.27,128.55; 128.49,128.03,126.40,120.66,118.21,117.42; 110.53,105.65,70.43,51.40,39.51,23.13; ES-MS:306.14 [M +]; Ee value is determined (4.6 mm * 25 cm, n-hexane/i-PrOH=90/10, λ=254nm, 0.8 ml/min), t by chiralcel AD-H post by chirality HPLC minor=33.0 min, t major=40.1 min, 97% ee.
3i, white powder, 72% yield, m.p.162-164 ° of C, [α] d 20=+73 (c=0.5, MeOH); H NMR (500 MHz, DMSO) δ 10.78 (s, 1H), 8.17 (d, j=8.8 Hz, 2H), 7.99 (t, j=5.8 Hz, 1H), 7.67 (d, j=8.7 Hz, 2H), 7.46 (d, j=7.9 Hz, 1H), 7.10 – 7.03 (m, 2H), 6.96 (t, j=7.3 Hz, 1H), 5.54 (d, j=4.5 Hz, 1H), 4.47 – 4.39 (m, 1H), 3.33 – 3.17 (m, 2H), 2.68 – 2.54 (m, 2H); 13c NMR (126 MHz, DMSO) δ 169.48,147.20,144.70,136.18,130.08,127.06,122.94,122.45,120.94,118.20,111.47,111.33,75.14,62.16,39.51,24.95; IR (KBr) v/cm -1: 3309,1642,1522,1352,1113,702; HRMS (ES +) caculated for C 19h 17n 3o 4[M+Na] +=374.1162, found=374.1161; Ee value is determined (4.6 mm * 25 cm, n-hexane/i-PrOH=90/10, λ=254nm, 0.8 ml/min), t by chiralcel AD-H post by chirality HPLC minor=40.1 min, t major=26.8 min, >99% ee.
3j, white powder, 75% productive rate, 193 ° of C of m.p. 190 –, [α] d 20=+7.3 (c=0.5, CHCl 3), [lit [16]: m.p. 185-191, [α] d 20=+6.9 (0.5, CHCl 3)]; 1h NMR (500 MHz, CDCl3) δ 7.92 (br s, 1 H), 7.53 (dd; J=6.8,1.6 Hz, 1 H), 7.33 – 7.24 (m; 5 H), 7.20 (dd, J=6.8 Hz, 2 Hz; 1 H), 7.15 (m, 1 H), 7.12 (m; 1 H), 4.96 (br, J=6.6 Hz; 1 H), 4.37 (d, J=6.0 Hz; 1 H), 4.34 (v br s), 3.96 (m; 1 H), 3.49 (m, 1 H); (3.41 m, 1 H), 3.03 (m; 1 H), 2.84 (s, 3 H); 13c NMR (100 MHz, CDCl 3) δ 173.5,141.0,135.2,132.2,129.3,128.7,127.5,127.2,122.1,119.4,117.5,110.7,106.6,73.8,54.3,46.4,34.2,22.8. IR (KBr) v/cm -1: 3301,2926,1640,1495,1461,1392,1360,1340,1183,1066,909,734,700; HRMS (ES +) caculated for C 20h 20o 2n 2[M] +=320.1525; Found:320.1530; Ee value is determined (4.6 mm * 25 cm, n-hexane/i-PrOH=90/10, λ=254nm, 0.8 ml/min), t by chiralcel AD-H post by chirality HPLC major=34.4 min, t minor=63.9 min, 97% ee.
embodiment 3application pharmacological testing
Test-compound neuroprotective, antioxygenation, anti-brain cell inflammatory effect and cell toxicity test.Experimental result is in Table 6, shown in table 7, table 8 and table 9.From table 6, table 7, table 8 and table 9, test-compound neuroprotective and antioxygenation are very low.As can be seen from Table 8, except 3g, other compound all has the effect of the inflammatory reaction that suppresses significantly the generation of rat microglia, and wherein 3c effect is the strongest.Meanwhile, as can be seen from Figure 1, cytotoxicity experiment shows that compound of the present invention does not have cytotoxicity.
The cerebral protection of the nerve injury that tested group of compound of table 6 causes the cultured rat cerebellar granule neurone nutritive deficiency of former culture
Note: the cell survival rate of blank group (DMSO treatment group) is 100%, the average survival rate of cell of negative control group (nutritive deficiency test group) is 38.8 ± 1.4%.Positive control is N-acetylcystein (NAC, this compound of bibliographical information is a kind of antioxidant), and the cell survival rate of this group is 53.7 ± 1.2% (10 mM).
The cerebral protection of the PC12 neural cell injury that tested group of compound of table 7 causes hydrogen peroxide
Note: the cell survival rate of blank group (DMSO treatment group) is 100%, and the cell survival rate of hydrogen peroxide treatment group is 61.9 ± 3.8%.Positive control is that the cell survival rate of this group of N-acetylcystein (NAC, this compound of bibliographical information is a kind of antioxidant) is 87.8 ± 3.8% (10 mM).Cell survival is analyzed and is measured through MTT.
The provide protection in the primary cultured rat cerebellar granule neuronal damage of Pidolidone induction of tested group of compound of table 8
Note: the cell survival rate of blank group (DMSO treatment group) is 100%, the average survival rate of cell of negative control group (L-glutamic acid treatment group) is 48.1%.
The restraining effect that table 9 test-compound discharges inflammatory factor TNFalpha in lipopolysaccharide-induced BV-2 microglia
Compound number Test event Lipopolysaccharide-induced rate (1 μ M) Lipopolysaccharide-induced rate (10 μ M)
3a The effect of anti-neuritis disease 102.0 ± 7.7 51.4 ± 5.3
3b The effect of anti-neuritis disease 96.3 ± 7.5 45.9 ± 3.4
3c The effect of anti-neuritis disease 72.8 ± 5.4 26.9 ± 3.6
3d The effect of anti-neuritis disease 108.0 ± 6.9 36.5 ± 3.7
3e The effect of anti-neuritis disease 105.9 ± 7.6 58.0 ± 5.1
3f The effect of anti-neuritis disease 94.5 ± 7.7 65.0 ± 6.3
3g The effect of anti-neuritis disease 112.4 ± 11.8 97.1 ± 8.6
3h The effect of anti-neuritis disease 104.5 ± 6.1 55.5 ± 5.6
3i The effect of anti-neuritis disease 90.9 ± 5.3 63.6 ± 6.5
3j The effect of anti-neuritis disease 105.9 ± 6.3 52.3 ± 5.2
Note: BV-2 microglia adds 100 ng/ml lipopolysaccharides single culture, or add lipopolysaccharides incubated cell after test-compound pre-treatment 2 h of various dose.After cell cultures 6 h, the burst size of cytokine TNF alpha is measured by ELISA method.Result is expressed with the form of lipopolysaccharide-induced rate.

Claims (10)

1. a class Balasubramide derivative, is characterized in that, its structural formula is as shown in formula I:
（Ⅰ），
Wherein, R 1for H or-CH 3; R is respectively Ph, 3-F-C 6h 4, 4-F-C 6h 4, 3-Cl-C 6h 4, 4-Cl-C 6h 4, 3-Br-C 6h 4, 4-Br-C 6h 4, 4-NO 2-C 6h 4or 3-CF 3-C 6h 4.
2. the application of Balasubramide derivative described in claim 1, is characterized in that, is applied to the preparation treatment cerebral protection medicine aspect relevant to neurocyte.
3. the application of Balasubramide derivative described in claim 1, is characterized in that, is applied to prepare anti-neuritis disease drug aspect.
4. application according to claim 2, is characterized in that, is by formula R shown in formula I in claim 1 1for H and R are 4-F-C 6h 4the compound characterizing is applied to the preparation treatment cerebral protection medicine aspect relevant to neurocyte.
5. application according to claim 3, is characterized in that, is by formula R shown in formula I in claim 1 1for H and R are 4-F-C 6h 4the compound characterizing is applied to prepare anti-neuritis disease drug aspect.
The preparation method of 6.Balasubramide and derivative thereof, is characterized in that, comprises the following steps:
S1. one kettle way catalysis trans-Cinnamylaldehyde and derivative epoxidation thereof, obtain α, beta epoxide carboxylicesters;
S2. by S1 gained α, beta epoxide carboxylicesters and tryptamines and analogue effect thereof, obtain prebalamide and derivative thereof;
S3. with Yb (CF 3sO 3) 3for catalyzer, make the prebalamide or derivatives thereof cyclization respectively of S2 gained, synthetic balasubramide and derivative thereof.
7. preparation method according to claim 5, is characterized in that, one kettle way catalysis trans-Cinnamylaldehyde and derivative epoxidation thereof comprise the following steps described in S1:
S11. under condition of ice bath, with 40% H 2o 2the aqueous solution is oxygenant, uses the S-diphenylprolinol triethyl silicon a series of trans-Cinnamylaldehyde of ether catalysis and derivative epoxidation thereof;
S12. at ambient temperature, S11 gained reaction solution dilutes with methyl alcohol, adds NBS and sodium carbonate, synthetic α, beta epoxide carboxylicesters.
8. described in claim 6 or 7, preparation method prepares Balasubramide and derivative thereof, is characterized in that, its structural formula is as shown in formula I:
（Ⅰ），
Wherein, R 1for H or-CH 3; R is Ph, 3-F-C 6h 4, 4-F-C 6h 4, 3-Cl-C 6h 4, 4-Cl-C 6h 4, 3-Br-C 6h 4, 4-Br-C 6h 4, 4-NO 2-C 6h 4or 3-CF 3-C 6h 4.
9. the application of Balasubramide and derivative thereof described in claim 8, is characterized in that, is applied to the preparation treatment cerebral protection medicine aspect relevant to neurocyte.
10. the application of Balasubramide and derivative thereof described in claim 8, is characterized in that, is applied to prepare anti-neuritis disease drug aspect.
CN201410260588.4A 2014-06-12 2014-06-12 Balasubramide and derivative thereof and synthetic method and application Active CN104003991B (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201510756523.3A CN105343061B (en) 2014-06-12 2014-06-12 The application of Balasubramide derivatives and preparation method
CN201410260588.4A CN104003991B (en) 2014-06-12 2014-06-12 Balasubramide and derivative thereof and synthetic method and application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410260588.4A CN104003991B (en) 2014-06-12 2014-06-12 Balasubramide and derivative thereof and synthetic method and application

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201510756523.3A Division CN105343061B (en) 2014-06-12 2014-06-12 The application of Balasubramide derivatives and preparation method

Publications (2)

Publication Number Publication Date
CN104003991A true CN104003991A (en) 2014-08-27
CN104003991B CN104003991B (en) 2016-05-25

Family

ID=51364924

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201510756523.3A Active CN105343061B (en) 2014-06-12 2014-06-12 The application of Balasubramide derivatives and preparation method
CN201410260588.4A Active CN104003991B (en) 2014-06-12 2014-06-12 Balasubramide and derivative thereof and synthetic method and application

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201510756523.3A Active CN105343061B (en) 2014-06-12 2014-06-12 The application of Balasubramide derivatives and preparation method

Country Status (1)

Country Link
CN (2) CN105343061B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110684027A (en) * 2019-09-12 2020-01-14 广东药科大学 Application of dextro-fluoro-barnacamide and derivative thereof and preparation method of derivative

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103169696A (en) * 2011-12-26 2013-06-26 中国医学科学院药物研究所 Use of effective components of Clausena lansium for treating neurodegenerative diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103169696A (en) * 2011-12-26 2013-06-26 中国医学科学院药物研究所 Use of effective components of Clausena lansium for treating neurodegenerative diseases

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BARBARA RIEMER，等: "TRYPTAMINE DERIVED AMIDES FROM CLAUSENA INDICA", 《PHYTOCHEMISTRY》 *
CHANGWU ZHENG,等: "Highly Efficient Asymmetric Epoxidation of Electron-Deficient α,β-Enones and Related Applications to Organic Synthesis", 《ADVANCED SYNTHESIS & CATALYSIS》 *
LUO YANG等: "Highly Efficient and Stereoselective N-Vinylation of Oxiranecarboxamides and Unprecedented 8-endo-Epoxy-arene Cyclization:Expedient and Biomimetic Synthesis of Some Clausena Alkaloids", 《ORGANIC LETTERS》 *
MAIRA JUÁREZ-CALDERÓN，等: "Synthesis of the indoloazocine derivatives from a chiral indol amide-stabilized sulfur ylide", 《TETRAHEDRON LETTERS》 *
ZHENG CHANG WU,等: "Asymmetric epoxidation of α,β-unsaturated ketones using α,α-diarylprolinols as catalysts", 《CHINESE SCIENCE BULLETIN》 *
王德先，等: "含三元环腈的生物转化反应与应用", 《化学进展》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110684027A (en) * 2019-09-12 2020-01-14 广东药科大学 Application of dextro-fluoro-barnacamide and derivative thereof and preparation method of derivative
CN110684027B (en) * 2019-09-12 2020-08-25 广东药科大学 Application of dextro-fluoro-barnacamide and derivative thereof and preparation method of derivative

Also Published As

Publication number Publication date
CN105343061A (en) 2016-02-24
CN104003991B (en) 2016-05-25
CN105343061B (en) 2018-03-20

Similar Documents

Publication Publication Date Title
DE102010005953A1 (en) Process for the preparation of nebivolol
CN102659888B (en) Cucurbitacin derivatives and preparation method thereof
CN111138443B (en) Preparation method for total synthesis of 4' -demethylepipodophyllotoxin
Qu et al. Chromatography‐crystallization hybrid process for artemisinin purification from Artemisia annua
CN102010387B (en) Method for purifying orlistat
CN102372723B (en) Method for extracting arglabin from artemisia myriantha
CN112707795B (en) Preparation method of Icetexane type abietane diterpene
CN102093374A (en) Method for efficiently extracting camptothecin derivative
CN102827106B (en) A kind of 10-DAB method for extraction and purification
CN104003991A (en) Balasubramide, derivative of balasubramide, synthesis method and application
CN111362990B (en) Antitumor drug LND1026-034 and synthetic method thereof
CN106905339B (en) Method for purifying phillygenin from forsythia suspense leaves
Oizumi et al. Synthesis of Procyanidins C2 and C1 Using Lewis Acid Mediated Equimolar Condensation
KR20070060714A (en) A mass production method of brazilein from caesalpinia sappan l
CN108947953B (en) Synthetic method of flavonoid derivative
CN101270119B (en) Technique for purifying spherosinin from leguminosae pointvetch or milk vetch
CN109369772B (en) Synthetic method and anti-tumor application of phenanthridine nitidine derivatives
CN109305970B (en) Preparation and application of 1, 7-disubstituted aminomethyl-2, 8-dihydroxy-Tr ger's Base catalyst
CN109320488B (en) Water phase one-pot synthesis method of 3-hydroxyflavone and derivatives thereof
Liu et al. A novel, stereoselective and practical protocol for the synthesis of 4β-aminopodophyllotoxins
CN104592253B (en) Novel synthesis method of temsirolimus
CN105566424A (en) Method for preparing calcium dibutyryladenosine cyclophosphate
Veidenberg et al. An efficient and highly stereoselective approach to trans-2, 5-disubstituted-tetrahydrofuran and trans-2, 6-disubstituted-tetrahydropyran derivatives
CN103694229A (en) Puerarin derivatives and preparation methods thereof
Chang et al. Secondary metabolites from magnolia kachirachirai

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CP01 Change in the name or title of a patent holder
CP01 Change in the name or title of a patent holder

Address after: 510224 Haizhuqu District City, Guangzhou Province Po Po Kong Han straight street, No. 40

Patentee after: Guangdong Pharmaceutical University

Address before: 510224 Haizhuqu District City, Guangzhou Province Po Po Kong Han straight street, No. 40

Patentee before: Guangdong Pharmaceutical University